Shots:
- The new data from the post-approval study evaluates the effectiveness & safety of Truxima (CT-P10) in patients with DLBCL in a real-world setting across Europe
- Results: @30mos. post-index, 67% had not experienced disease progression with OS (74%), three-quarters patients achieved complete or partial response @30mos., well tolerated with AEs while response rates, survival rates & overall safety profile showed consistency with reference product
- The company also presents real-world data of CT-P10 for NHL & CLL which showed 10% of patients experienced an IRR & were generally well-tolerated, patients achieved a complete response or partial response @6mos. observation period
Click here to read full press release/ article | Ref: Business Wire | Image: Pulse News Korea
The post Celltrion Presents Real-World Data of Truxima (biosimilar, rituximab) for Diffuse Large B-Cell Lymphoma at EHA 2021 first appeared on PharmaShots.
